The biopharmaceutical industry, like many others, is moving quickly to adopt AI, and early excitement is justified. Productivity gains attributed to AI are being widely documented, including 28% faster target identification, 22% faster biomarker identification, and 20% faster compound screening.

Yet the broader sentiment around AI readiness is more nuanced. While most executives believe that AI will transform drug development, less than half agree that their organizations are actually ready to deploy it. And those organizations that are scaling often lack the prerequisites for long-term AI viability, like clear alignment on goals and a workforce prepared to fully embrace new tools.

This gap reflects a clear distinction between speed and preparedness. For example, an automated R&D agent that accelerates clinical trial candidate identification is only valuable if it’s grounded in the right objective. Without clarity on what success means for the patient, speed alone can become an expensive misdirection.

To achieve both, organizations must build a strong foundation that anchors AI deployments in three critical areas: define measurable, human-centered outcomes, focus on intelligent, integrated systems, and maintain expertise and oversight. By strategically embedding AI across workflows, scientists and clinicians can focus on what pharma is truly meant to do––get better treatments to patients faster and more efficiently.

Defining Meaningful Outcomes Before Deployment

Effective AI strategies begin with a deep look at what success actually means. Beyond setting time-to-market targets or deployment timelines, organizations must establish the outcomes that AI should serve, such as patient efficacy and safety, market access, affordability, or clinical trial diversity.

This work requires cross-functional alignment across R&D, clinical, commercial, and regulatory teams to collectively define what an AI “win” looks like. Without this, each function optimizes independently and risks compromising another goal. A drug discovery algorithm may identify compounds that perform well computationally but don't account for patient accessibility, clinical effectiveness, or regulatory feasibility. The result is expending energy on fragmented projects, rather than acting as a united force for patient well-being.

Organizations that invest in outcome-setting can better allocate resources and prioritize investments with justified rationale and agility. In the end, moving towards a patient-centered outcome is the distinction between separate AI pilots and a deliberate strategy.

Building the Data Foundations AI Depends On

Even the most advanced AI models are only as effective as the data that feeds them. Yet many biopharma organizations are attempting to scale AI without fully addressing data quality, accessibility, and integration across the enterprise. When organizations shift patient-centric ways of working, the consequences of skipping this step become obvious and could be substantial.

The disconnect between awareness and action is stark. While a majority of organizations identify improving data integration as a priority, only 37% currently qualify as “data frontrunners,” meaning they actively invest in both data infrastructure and data-driven culture. Teams also continue to struggle internally, as 22% report inadequacy in data accessibility. For an industry where decisions carry profound patient consequences, this is a risk.

Leaders can build a rigorous data foundation by zooming in on three elements:

1. Accuracy – ensuring clinical, R&D, and commercial data are clean, validated, and standardized.
2. Integration – connecting siloed data systems so AI has access to the complete picture, from molecule to market to patient.
3. Governance – establishing clear ownership, security, and access protocols so data remains trustworthy and compliant throughout the organization.

When these pillars are in place, scientists and clinicians can develop genuine confidence in the outputs they're given, which enables faster and more assured decision-making. This confidence empowers teams to focus on the tasks that require uniquely human skills, like interpreting insights, applying judgment, and interrogating whether an output truly makes sense in larger context of the business.

Maintaining Human Oversight and Judgement

As AI takes on increasingly complex tasks, leaders must ensure that the time saved can be spent on making decisions that require reasoning and broader context. While automation can accelerate analysis, judgement remains essential when evaluating outcomes that affect patient safety, real‑world efficacy, and access.

This shift is already underway, with 76% of leaders expecting AI to change roles and responsibilities. But the critical question is whether organizations are adapting intentionally.

In practice, this means preserving human judgement at key parts of the process––like having a clinician assess whether trial data reflects real-world efficacy or looping in a commercial leader to make sure a treatment would be widely accessible in the market.

One way to reinforce this balance is by continually emphasizing skills like reasoning, empathy, data literacy, and collaboration. This supports a culture that embraces experimentation while maintaining accountability. At the same time, leadership plays a critical role by modeling how AI outputs are questioned, contextualized, and governed responsibly.

When human oversight is deliberately maintained, AI enables teams to reduce operational bottlenecks while increasing confidence in the decisions behind them.

Anchoring AI in What Matters Most

The biopharma industry is facing a productivity transformation. AI has the power to reshape drug discovery, development, and access—but only if deployed with discipline.

There are no shortcuts to responsible AI scaling. Layering governance on top of poorly sequenced deployments only adds complexity, increases risk, and undermines trust.

Instead, the path forward requires deliberate sequencing, where organizational culture actually changes alongside technology use. Factors like building trust and reinforcing human expertise must mutually benefit AI efforts, rather than compete for attention. For CXOs, this is the starting point: convene leadership across R&D, clinical, commercial, and regulatory to define what AI success looks like before deployment begins.

By anchoring AI investments in patient-centered outcomes, dependable data, and human expertise, pharma leaders can advance discoveries that serve the broader mission of better patient outcomes.